LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: A single-lead ECG based cardiotoxicity detection in patients on polychemotherapy.

    Mesitskaya, Dinara F / Fashafsha, Zaki Z A / Poltavskaya, Maria G / Andreev, Denis A / Levshina, Anna R / Sultygova, Elizaveta A / Gognieva, Daria / Chomakhidze, Petr / Kuznetsova, Natalia / Suvorov, Alexander / Marina I, Sekacheva / Poddubskaya, Elena / Novikova, Alena / Bykova, Aleksandra / Kopylov, Philipp

    International journal of cardiology. Heart & vasculature

    2024  Volume 50, Page(s) 101336

    Abstract: Background: Anti-cancer treatment can be fraught with cardiovascular complications, which is the most common cause of death among oncological survivors. Without appropriate cardiomonitoring during anti-cancer treatment, it becomes challenging to detect ... ...

    Abstract Background: Anti-cancer treatment can be fraught with cardiovascular complications, which is the most common cause of death among oncological survivors. Without appropriate cardiomonitoring during anti-cancer treatment, it becomes challenging to detect early signs of cardiovascular complications. In order to achieve higher survival rates, it is necessary to monitor oncological patients outpatiently after anti-cancer treatment administration. In this regard, we aim to evaluate the efficacy of single-lead ECG remote monitoring to detect cardiotoxicity in cancer patients with minimal cardiovascular diseases after the first cycle of polychemotherapy.
    Materials and methods: The study included patients 162 patients over 18 years old with first diagnosed different types of solid tumors, planed for adjuvant (within 8 weeks after surgery) or neoadjuvant polychemotherapy. All patients were monitored, outpatiently, during 14-21 days (depending on the regimen of polychemotherapy) after polychemotherapy administration using single-lead ECG.
    Results: QTc > 500 mc prolongation was detected in 8 patients (6.6 %), first-diagnosed arial fibrillation was detected in 11 patients (9 %) in period after chemotherapy administration. Moreover, left ventricular diastolic dysfunction using single-lead ECG after polychemotherapy was detected in 49 (40.1 %) patients with sensitivity 80 %, specificity 95 %, AUC 0.88 (95 % CI, 0.82-0.93).
    Conclusions: The side effects of cancer treatment may cause life-threatening risks. Early identification of cardiotoxicity plays a vital role in the solution of this problem. Using portable devices to detect early cardiotoxicity is a simple, convenient and affordable screening method, that can be used for promptly observation of patients.
    Language English
    Publishing date 2024-01-20
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 2818464-6
    ISSN 2352-9067
    ISSN 2352-9067
    DOI 10.1016/j.ijcha.2024.101336
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel.

    Mirzaev, Karin B / Osipova, Darya V / Kitaeva, Elena J / Shprakh, Vladimir V / Abdullaev, Sherzod P / Andreev, Denis A / Mumladze, Robert B / Sychev, Dmitriy A

    Drug metabolism and personalized therapy

    2019  Volume 34, Issue 3

    Abstract: Background The aim of this study was to evaluate the association of the carriage of the rs2244613 polymorphism of the CES1 gene with clopidogrel resistance as well as to evaluate the effectiveness of antiplatelet therapy in the carriers of this marker ... ...

    Abstract Background The aim of this study was to evaluate the association of the carriage of the rs2244613 polymorphism of the CES1 gene with clopidogrel resistance as well as to evaluate the effectiveness of antiplatelet therapy in the carriers of this marker who have had acute coronary syndrome (ACS). This study also analyzes the procedure of percutaneous coronary intervention and compares the rs2244613 carrier rate between patients with ACS and healthy participants. Methods The study involved 81 patients diagnosed with ACS and 136 conditionally healthy participants. The optical detection of platelet agglutination by VerifyNow was employed to measure residual platelet reactivity in patients with ACS. The rs2244613 polymorphism was determined using real-time polymerase chain reaction. Results According to the results, the AA genotype of the rs2244613 polymorphism of the CES1 gene was detected in 37 patients (45.6%), the CA genotype in 42 patients (51.8%) and the CC genotype in 2 patients (2.6%). The level of residual platelet reactivity in rs2244613 carriers was higher compared with patients who did not have this allelic variant: 183.23 PRU ± 37.24 vs. 154.3 PRU ± 60.36 (p = 0.01). The frequencies of the minor allele C were 28.4% and 28.3% in patients with ACS and healthy participants, respectively. The results of the linear statistical model PRU due to CES1 genotype were as follows: df = 1, F = 6.96, p = 0.01). The standardized beta was 0.285 (p = 0.01) and R2 was 0.081. However, we also added CYP2C19*2 and *17 into the linear regression model. The results of the model were as follows: df = 3, F = 5.1, p = 0.003) and R2 was 0.166. Conclusions We identified a statistically significant correlation between the carriage of the rs2244613 polymorphism of the CES1 gene and the level of residual platelet aggregation among patients with ACS and the procedure of percutaneous coronary intervention.
    MeSH term(s) Acute Coronary Syndrome/diagnosis ; Acute Coronary Syndrome/drug therapy ; Acute Coronary Syndrome/genetics ; Adult ; Carboxylic Ester Hydrolases/blood ; Carboxylic Ester Hydrolases/genetics ; Clopidogrel/pharmacology ; Female ; Genotype ; Humans ; Male ; Middle Aged ; Platelet Aggregation/drug effects ; Platelet Aggregation Inhibitors/pharmacology ; Polymorphism, Genetic/genetics ; Purinergic P2Y Receptor Antagonists/pharmacology ; Receptors, Purinergic P2Y12/metabolism
    Chemical Substances Platelet Aggregation Inhibitors ; Purinergic P2Y Receptor Antagonists ; Receptors, Purinergic P2Y12 ; Clopidogrel (A74586SNO7) ; Carboxylic Ester Hydrolases (EC 3.1.1.-) ; CES1 protein, human (EC 3.1.1.1)
    Language English
    Publishing date 2019-09-27
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2822040-7
    ISSN 2363-8915 ; 2363-8907
    ISSN (online) 2363-8915
    ISSN 2363-8907
    DOI 10.1515/dmpt-2018-0039
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes.

    Mirzaev, Karin B / Rytkin, Eric / Ryzhikova, Kristina A / Grishina, Elena A / Sozaeva, Zhannet A / Fedorinov, Denis S / Konova, Olga D / Giliarov, Michael Iu / Belyakova, Galina A / Andreev, Denis A / Sychev, Dmitriy A

    Drug metabolism and personalized therapy

    2018  Volume 33, Issue 3, Page(s) 109–118

    MeSH term(s) ATP Binding Cassette Transporter, Subfamily B/blood ; ATP Binding Cassette Transporter, Subfamily B/genetics ; Acute Coronary Syndrome/blood ; Acute Coronary Syndrome/drug therapy ; Acute Coronary Syndrome/genetics ; Blood Platelets/drug effects ; Blood Platelets/metabolism ; Clopidogrel/chemistry ; Clopidogrel/metabolism ; Clopidogrel/pharmacokinetics ; Cytochrome P-450 CYP2C19/blood ; Cytochrome P-450 CYP2C19/genetics ; Cytochrome P-450 CYP3A/blood ; Cytochrome P-450 CYP3A/genetics ; Cytochrome P450 Family 4/blood ; Cytochrome P450 Family 4/genetics ; Dose-Response Relationship, Drug ; Female ; Genotype ; Humans ; Male ; Middle Aged ; Platelet Aggregation Inhibitors/administration & dosage ; Platelet Aggregation Inhibitors/pharmacology ; Polymorphism, Genetic/genetics
    Chemical Substances ABCB1 protein, human ; ATP Binding Cassette Transporter, Subfamily B ; Platelet Aggregation Inhibitors ; Clopidogrel (A74586SNO7) ; CYP2C19 protein, human (EC 1.14.14.1) ; CYP3A5 protein, human (EC 1.14.14.1) ; Cytochrome P-450 CYP2C19 (EC 1.14.14.1) ; Cytochrome P-450 CYP3A (EC 1.14.14.1) ; Cytochrome P450 Family 4 (EC 1.14.14.1) ; CYP4F2 protein, human (EC 1.14.14.78)
    Language English
    Publishing date 2018-08-21
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2822040-7
    ISSN 2363-8915 ; 2363-8907
    ISSN (online) 2363-8915
    ISSN 2363-8907
    DOI 10.1515/dmpt-2018-0006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Do

    Rytkin, Eric / Mirzaev, Karin B / Grishina, Elena A / Smirnov, Valeriy V / Ryzhikova, Kristina A / Sozaeva, Zhannet A / Giliarov, Michael Iu / Andreev, Denis A / Sychev, Dmitriy A

    Pharmacogenomics and personalized medicine

    2017  Volume 10, Page(s) 243–245

    Abstract: Aim: The aim of this study was to determine the impact of : Patients and methods: Seventy-six patients (median age 63, range 37-91 years) with an ACS who underwent PCI were screened for : Results: Low mean 6-beta-hydroxycortisol/cortisol ratio is ... ...

    Abstract Aim: The aim of this study was to determine the impact of
    Patients and methods: Seventy-six patients (median age 63, range 37-91 years) with an ACS who underwent PCI were screened for
    Results: Low mean 6-beta-hydroxycortisol/cortisol ratio is indicative of impaired CYP3A4 activity and was associated with higher risk of thrombosis (
    Conclusion: We did not find evidence that the presence of
    Language English
    Publishing date 2017-09-18
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2508173-1
    ISSN 1178-7066
    ISSN 1178-7066
    DOI 10.2147/PGPM.S143250
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top